Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Cardiology
•
Advanced Heart Failure and Transplant
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
Related Questions
What is your approach to initiating spironolactone in patients with end stage kidney disease and heart failure?
What is your approach to weaning dialysis in a patient with AKI on CKD and CHF who now has resolved AKI but a history of recurrent episodes of decompensated heart failure?
How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
In patients with resolved LV thrombus post-MI after 3-6 months of anticoagulation, would you consider surveillance imaging for thrombus recurrence if there is persistent apical akinesis?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
When would be your threshold to consider obtaining an exercise RHC for undifferentiated dyspnea to help diagnose HFpEF?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
